ANI Other Current Assets vs Property Plant And Equipment Gross Analysis
ANIP Stock | USD 58.92 0.27 0.46% |
ANI Pharmaceuticals financial indicator trend analysis is way more than just evaluating ANI Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ANI Pharmaceuticals is a good investment. Please check the relationship between ANI Pharmaceuticals Other Current Assets and its Property Plant And Equipment Gross accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.
Other Current Assets vs Property Plant And Equipment Gross
Other Current Assets vs Property Plant And Equipment Gross Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ANI Pharmaceuticals Other Current Assets account and Property Plant And Equipment Gross. At this time, the significance of the direction appears to have strong relationship.
The correlation between ANI Pharmaceuticals' Other Current Assets and Property Plant And Equipment Gross is 0.74. Overlapping area represents the amount of variation of Other Current Assets that can explain the historical movement of Property Plant And Equipment Gross in the same time period over historical financial statements of ANI Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of ANI Pharmaceuticals' Other Current Assets and Property Plant And Equipment Gross is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Assets of ANI Pharmaceuticals are associated (or correlated) with its Property Plant And Equipment Gross. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant And Equipment Gross has no effect on the direction of Other Current Assets i.e., ANI Pharmaceuticals' Other Current Assets and Property Plant And Equipment Gross go up and down completely randomly.
Correlation Coefficient | 0.74 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Other Current Assets
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.Property Plant And Equipment Gross
Most indicators from ANI Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ANI Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.At this time, ANI Pharmaceuticals' Selling General Administrative is relatively stable compared to the past year. As of 02/18/2025, Enterprise Value Over EBITDA is likely to grow to 11.97, while Issuance Of Capital Stock is likely to drop slightly above 71.8 M.
ANI Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
ANI Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ANI Pharmaceuticals fundamental ratios Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 461.2M | 771.6M | 760.1M | 904.4M | 1.0B | 1.1B | |
Other Current Liab | 50.1M | 60.0M | 65.5M | 99.8M | 114.7M | 120.5M | |
Total Current Liabilities | 78.6M | 87.5M | 99.4M | 145.5M | 167.3M | 175.7M | |
Total Stockholder Equity | 195.7M | 358.7M | 338.5M | 457.6M | 526.2M | 552.6M | |
Property Plant And Equipment Net | 41.3M | 52.7M | 43.2M | 44.6M | 51.3M | 53.8M | |
Net Debt | 177.8M | 187.1M | 238.3M | 64.5M | 74.2M | 38.9M | |
Retained Earnings | (5.0M) | (47.8M) | (97.3M) | (80.1M) | (72.1M) | (75.7M) | |
Accounts Payable | 11.3M | 23.0M | 29.3M | 36.7M | 42.2M | 44.3M | |
Cash | 7.9M | 100.3M | 48.2M | 221.1M | 254.3M | 267.0M | |
Non Current Assets Total | 290.9M | 449.8M | 415.8M | 384.6M | 442.3M | 464.4M | |
Cash And Short Term Investments | 7.9M | 100.3M | 48.2M | 221.1M | 254.3M | 267.0M | |
Common Stock Shares Outstanding | 12.0M | 12.6M | 16.3M | 18.2M | 20.9M | 22.0M | |
Liabilities And Stockholders Equity | 461.2M | 771.6M | 760.1M | 904.4M | 1.0B | 1.1B | |
Other Current Assets | 5.9M | 11.3M | 25.2M | 25.4M | 29.2M | 30.7M | |
Total Liab | 265.5M | 412.9M | 421.5M | 446.8M | 513.8M | 539.5M | |
Property Plant And Equipment Gross | 41.3M | 75.6M | 76.0M | 77.5M | 89.2M | 93.6M | |
Total Current Assets | 170.3M | 321.8M | 344.3M | 519.8M | 597.8M | 627.7M | |
Other Stockholder Equity | 212.1M | 384.7M | 398.8M | 504.0M | 579.6M | 608.6M | |
Accumulated Other Comprehensive Income | (11.4M) | (3.1M) | 12.2M | 8.9M | 8.0M | 8.4M | |
Short Long Term Debt Total | 185.7M | 287.4M | 286.5M | 285.7M | 328.5M | 344.9M | |
Short Term Debt | 115.7M | 9.9M | 13.2M | 850K | 977.5K | 928.6K | |
Current Deferred Revenue | 451K | 80K | 87K | 32.5M | 37.4M | 39.2M | |
Non Currrent Assets Other | 802K | 2.2M | 2.6M | 12.1M | 13.9M | 14.6M | |
Non Current Liabilities Total | 186.9M | 325.3M | 322.1M | 301.3M | 346.5M | 363.9M | |
Net Receivables | 95.8M | 128.5M | 165.4M | 162.1M | 186.4M | 195.7M | |
Net Tangible Assets | 28.8M | 3.6M | 36.7M | 58.7M | 52.8M | 55.5M | |
Other Assets | 44.6M | 57.5M | 75.1M | 92.7M | 106.6M | 112.0M | |
Long Term Debt | 172.4M | 286.5M | 285.7M | 284.8M | 327.5M | 343.9M | |
Retained Earnings Total Equity | 17.6M | (5.0M) | (47.8M) | (97.3M) | (111.9M) | (117.5M) | |
Inventory | 60.8M | 81.7M | 105.4M | 111.2M | 127.9M | 134.3M | |
Deferred Long Term Liab | 1.5M | 800K | 500K | 600K | 690K | 458.1K | |
Intangible Assets | 188.5M | 294.1M | 251.6M | 209.0M | 240.4M | 156.5M | |
Property Plant Equipment | 40.6M | 41.3M | 52.7M | 43.2M | 49.7M | 52.2M | |
Capital Surpluse | 200.8M | 214.4M | 387.8M | 403.9M | 464.5M | 237.5M | |
Other Liab | 7K | 201K | 31.0M | 35.1M | 40.3M | 42.3M |
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.